Measurement of progression-free survival, a widely used endpoint in cancer clinical trials, has methodological flaws that can lead to biased estimates.

Sutent (sunitinib malate) has received a European Association of Urology (EAU) recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma (mRCC).